GSK plc Sponsored ADR (LSE:GSK) is reshaping itself with a £1.9B cost-saving plan and £2.4B restructuring to move R&D to Cambridge, adopt AI and streamline ops while launching 25 late-stage trials by 2026, buoyed by Artemis-011 Phase III success and a $110M Relation Therapeutics AI tie-up.
Previous Week Recap
- GSK Plans £1.9B Savings: GSK (GSK) plans £1.9B savings by 2029 and a £2.4B restructuring to shift R&D to Cambridge, adopt AI, streamline ops, and start 25 late-stage trials by end-2026; shares rose ~6%.
- GSK plc ADR Artemis-011 Phase III Met: GSK plc ADR (GSK): Artemis-011 Phase III in relapsed osteosarcoma met its primary endpoint and showed no new safety signals, confirming trial success on the main efficacy measure.
- GSK Collaborates With Relation Therapeutics: GSK (GSK) agreed to a collaboration with Relation Therapeutics worth up to $110M to build large human cellular datasets and train AI models to find new drug targets using Relation’s MORGAN platform.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.